COMP <GO>
CPHI vs CELU // OPERATING MARGIN
China Pharma Holdings Inc. (NYSE) VS. Celularity Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: CPHI 5
— CELU 1
■ METRIC PARITY
LAST: $0.65 (+4.84%) • MKT CAP: $28.0M
operating-margins
-60.00%
LAST: $0.85 (-9.66%) • MKT CAP: $27.6M
operating-margins
-60.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CPHI VS. CELU)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CPHI | CELU | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | -3.20% | 24.40% | -27.60 | CELU | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -11.40% | -35.00% | +23.60 | CPHI | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.32% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -8.50% | -51.00% | +42.50 | CPHI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 1/9 | +3.00 | CPHI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.2 | 35.9 | +4.25 | CPHI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $28.0M | $27.6M | $403.9K | CPHI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CPHI REV | CELU REV | CPHI GROSS % | CELU GROSS % | CPHI FCF | CELU FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.1M | $26.6M | -3.2% | 24.4% | $88.9K | -$13.3M |
| FY 2024 | $4.5M | $54.2M | -43.8% | 72.4% | -$444.5K | -$6.6M |
| FY 2023 | $7.0M | $22.8M | — | — | -$699.7K | -$38.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CPHI // BETA —
CELU // BETA —